Welcome to our dedicated page for Ptc Therapeutics SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PTC Therapeutics filings document a Delaware biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under PTCT. Its Form 8-K reports cover quarterly and annual financial results, Regulation FD disclosures, product and pipeline updates, FDA-related communications, and board or compensation matters.
Proxy materials describe annual meeting governance, director elections, executive compensation, equity awards and related shareholder matters. The filing record also includes disclosures tied to rare-disease programs such as Sephience™ (sepiapterin), votoplam and Translarna™ (ataluren), along with the company’s capital structure and public-company reporting obligations.
PTCT reported a Rule 144 notice showing the sale of 20,960 shares by Fidelity Brokerage Services LLC via a stock option exercise on 06/25/2026 for cash. The filing also lists earlier dispositions by Zheng Y. Almstead: 52,003 shares on 04/01/2026, 23,749 shares on 06/22/2026, and 5,323 shares on 06/24/2026, with disclosed proceeds for each sale. Shares outstanding are shown as 82,949,338 as of 06/25/2026.
PTC Therapeutics’ Chief Technical Operations Officer Neil Gregory Almstead reported an options exercise and matching share sales in Common Stock. He exercised stock options for 23,749 shares at $25.69 per share, then sold 23,749 shares in open-market transactions at weighted average prices of about $80.61 and $81.21 per share under a written Rule 10b5-1 trading plan adopted on November 11, 2025. He also reports 2,737 shares of Common Stock held indirectly through his spouse.
PTCT filing reports Rule 144 dispositions by an insider and a scheduled issuer exercise. The filing lists two past dispositions by Neil G. Almstead: 52,003 common shares on 04/01/2026 for $3,590,359.84 and 23,749 common shares on 06/22/2026 for $1,921,431.84. The notice also lists 5,323 common shares to be sold on 06/24/2026 in a Stock Option Exercise by the issuer for cash.
PTC Therapeutics SVP and Chief Accounting Officer Christine Marie Utter reported an exercise-and-sell stock transaction. She exercised options to acquire 19,686 shares of common stock at $25.69 per share and sold 19,686 shares in the open market at $75.56 per share on the same date. After these transactions, she directly holds 70,199 shares of common stock and 15,314 stock options as shown in the derivative table. The filing notes the sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 17, 2026.
PTC Therapeutics executive Mark Elliott Boulding reported an exercise-and-sell transaction in company stock. On June 17, 2026, he exercised stock options to acquire a total of 10,522 shares of Common Stock at an exercise price of $46.54 per share.
On the same date he sold 10,462 shares in open-market transactions at weighted average prices around $78.50–$79.25 per share, executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 10, 2025. Following these transactions, he directly holds 105,272 shares of PTC Therapeutics common stock.
Filer submitted a Form 144 notice to sell common stock of PTCT. The filing lists 23,749 shares to be sold in a stock option exercise transaction on 06/22/2026. The excerpt also shows a prior sale of 52,003 shares on 04/01/2026 and a reported figure of 82,949,338 shares shown with the date 06/22/2026.
PTC Therapeutics, Inc. completed a private offering of $550,000,000 aggregate principal amount of 0.0% Convertible Senior Notes due 2031. The notes carry no regular interest, may only bear special interest in limited circumstances, and mature on June 15, 2031 unless earlier converted, redeemed or repurchased.
The notes are initially convertible at 9.3042 shares of common stock per $1,000 principal amount, equivalent to a conversion price of approximately $107.48 per share. PTC estimates net proceeds of about $535.5 million and is using approximately $328.8 million to repurchase for cash $222.0 million principal of its 1.50% Convertible Senior Notes due 2026, leaving $55.5 million of those existing notes outstanding. The new notes are senior unsecured obligations with customary conversion, redemption, repurchase and default provisions.
PTCT insider filing reports a proposed sale of 10,522 shares via a stock option exercise on 06/17/2026. The filing also lists prior dispositions by Mark Boulding of 2,265, 3,540 and 2,812 shares on 04/06/2026, 05/08/2026 and 05/15/2026, respectively. The exercise method is listed as cash.
PTC Therapeutics has priced a private Offering of $500.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2031, with an option for initial purchasers to buy an additional $50.0 million. PTC estimates net proceeds of about $486.8 million (or $535.5 million if the option is fully exercised).
The company expects to use approximately $328.8 million of the proceeds to repurchase for cash $222.0 million principal amount of its 1.5% Convertible Senior Notes due 2026, and to use the remainder for general corporate purposes, including potential additional 2026 note repurchases and repayment at maturity. The Notes mature on June 15, 2031, carry no coupon, and are convertible at an initial rate of 9.3042 shares per $1,000, implying a conversion price of about $107.48 per share, a roughly 40% premium to the $76.77 closing share price on June 15, 2026.